Board of Directors
The board of directors is the company’s highest decision-making body after the annual general meeting. According to the Swedish Companies Act, the board of directors is responsible for the company’s administration and organization, which means that the board of directors is responsible for, among other things, establishing goals and strategies, ensuring procedures and systems for evaluating established goals, continuously evaluating the company’s results and financial position, and evaluating the operational management. The board of directors is also responsible for ensuring that the annual report and interim reports are prepared in a timely manner. In addition, the board of directors appoints the company’s CEO.
The members of the board of directors are normally elected by the annual general meeting for the period until the end of the next annual general meeting. According to the company’s articles of association, the board of directors shall consist of a minimum of three and a maximum of eight Board members.
According to the Code, the Chairman of the board shall be elected by the annual general meeting and have a special responsibility for the management of the board’s work and for ensuring that the board’s work is well organized and carried out in an efficient manner.
The board of Directors has, in accordance with the Swedish Companies Act, adopted written rules of procedure for its work, which shall be evaluated, updated and re-adopted annually. The board meets regularly according to a programme established in the rules of procedure that includes certain mandatory decision points and certain decision points applicable if necessary. In addition to these Board meetings, additional board meetings may be convened to deal with matters that cannot be referred to an ordinary board meeting. In addition to the board meetings, the Chairman of the board and the CEO have an ongoing dialogue regarding the management of the company.
![](https://investor.eqlpharma.com/wp-content/uploads/christer-fahraeus-bw.jpg)
![](https://investor.eqlpharma.com/wp-content/uploads/anders-mansson-bw.jpg)
![](https://investor.eqlpharma.com/wp-content/uploads/per-ollermark-bw.jpg)
![](https://investor.eqlpharma.com/wp-content/uploads/per-svangren-bw.jpg)
![](https://investor.eqlpharma.com/wp-content/uploads/linda-neckmar-bw.jpg)
![](https://investor.eqlpharma.com/wp-content/uploads/nikunj-shah-bw.jpg)